Mineralys Therapeutics will report Q4 and full-year 2024 financial results on February 12, 2025.
Quiver AI Summary
Mineralys Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for conditions related to dysregulated aldosterone such as hypertension, chronic kidney disease, and obstructive sleep apnea, announced that it will disclose its financial results for the fourth quarter and full year of 2024 on February 12, 2025, before market opening. The company, based in Radnor, Pennsylvania, is developing lorundrostat, an orally administered aldosterone synthase inhibitor aimed at addressing cardiorenal disorders. A live conference call will be available for investors and interested parties, along with additional details on their website.
Potential Positives
- Mineralys Therapeutics is set to report its fourth quarter and full year financial results, indicating transparency and an ongoing commitment to keep investors informed.
- The company's focus on developing medicines for significant health issues like hypertension, CKD, and OSA highlights its potential impact on public health and market relevance.
- Mineralys's initial product candidate, lorundrostat, being a proprietary treatment, suggests a strong pipeline that could lead to competitive advantages in the biopharmaceutical market.
Potential Negatives
- Failure to provide forward-looking guidance may imply uncertainty regarding future performance, which could concern investors.
- Being a clinical-stage biopharmaceutical company might signal inherent risks in product development and market entry challenges.
- Announcement being centered around financial results could indicate potential existing vulnerabilities if the results are below expectations.
FAQ
When will Mineralys Therapeutics release its financial results?
Mineralys Therapeutics will report its financial results on February 12, 2025, before the markets open.
What is the focus of Mineralys Therapeutics?
Mineralys Therapeutics specializes in developing medicines for hypertension, chronic kidney disease, and obstructive sleep apnea.
How can I access the live webcast of the financial results?
The live webcast can be found on the “News & Events” page of the Mineralys Therapeutics website.
What is lorundrostat?
Lorundrostat is a proprietary, orally administered aldosterone synthase inhibitor developed by Mineralys Therapeutics for cardiorenal conditions.
Where is Mineralys Therapeutics located?
Mineralys Therapeutics is based in Radnor, Pennsylvania.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MLYS Insider Trading Activity
$MLYS insiders have traded $MLYS stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $MLYS stock by insiders over the last 6 months:
- DAVID MALCOM RODMAN (Chief Medical Officer) has made 0 purchases and 2 sales selling 30,508 shares for an estimated $458,463.
- JON CONGLETON (Chief Executive Officer) has made 0 purchases and 2 sales selling 33,604 shares for an estimated $372,515.
- ADAM SCOTT LEVY (CFO and Secretary) has made 0 purchases and 3 sales selling 21,514 shares for an estimated $243,867.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MLYS Hedge Fund Activity
We have seen 60 institutional investors add shares of $MLYS stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TCG CROSSOVER MANAGEMENT, LLC removed 714,920 shares (-22.4%) from their portfolio in Q3 2024, for an estimated $8,657,681
- ADAR1 CAPITAL MANAGEMENT, LLC added 704,035 shares (+2775.5%) to their portfolio in Q3 2024, for an estimated $8,525,863
- CATALYS PACIFIC, LLC removed 550,000 shares (-6.0%) from their portfolio in Q3 2024, for an estimated $6,660,500
- JENNISON ASSOCIATES LLC added 385,726 shares (+55.4%) to their portfolio in Q4 2024, for an estimated $4,748,287
- ROCK SPRINGS CAPITAL MANAGEMENT LP removed 378,932 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $4,588,866
- INTEGRAL HEALTH ASSET MANAGEMENT, LLC added 356,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $4,311,160
- EXODUSPOINT CAPITAL MANAGEMENT, LP removed 274,316 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $3,321,966
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2024, before the financial markets open on Wednesday, February 12, 2025.
| Wednesday, February 12 th @ 8:30 a.m. ET | |
| Domestic: | 1-800-717-1738 |
| International: | 1-646-307-1865 |
| Webcast: | Link |
A live webcast of the conference call may also be found on the “ News & Events ” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit
https://mineralystx.com
. Follow Mineralys on
LinkedIn
and
Twitter
.
Contact:
Investor Relations
[email protected]
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email:
[email protected]
